Study demonstrates a capsaicin hydrogel patch's comparable anti-inflammatory effects to diclofenac in myofascial pain syndrome, highlighting safety and effectiveness.
Background: Capsaicin, the primary pungent component of Capsicum annuum, exhibits significant anti-inflammatory and analgesic properties by acting on TRPV1 receptors and modulating COX-2 expression. However, its therapeutic use is limited by poor solubility, instability, and potential skin irritation. Myofascial Pain Syndrome (MPS), a prevalent musculoskeletal disorder, presents a need for safer and more effective topical treatments. This study aimed to develop and evaluate capsaicin loaded hydrogel patches for cytotoxic effects, anti-inflammatory properties, and pain relief. Methods and Results: A hydrogel patch containing 0.1% capsaicin was fabricated using polyvinyl alcohol (PVA), gelatin, glycerol, Tween 80, triethanolamine through the freeze–thaw technique. Structural analysis by GC-MS revealed bioactive constituents, predominantly dodecyl acrylate (45.78%), oleic acid (25.06%), and trans-oleic acid (7.52%), all known for their anti-inflammatory and skin-permeation-enhancing properties. FTIR confirmed the successful incorporation of capsaicin into the hydrogel matrix with characteristic shifts in N–H, C=O, and C–N functional groups, while UV-Vis spectroscopy supported capsaicin release over time. Cytotoxicity testing on human skin fibroblast (HSF) cells demonstrated high cell viability (>90%) at concentrations below 1 mg/mL, with an IC₅₀ of approximately 20 mg/mL, indicating low toxicity at therapeutic doses. The hydrogel exhibited dose-dependent anti-inflammatory activity. Notably, the anti-inflammatory efficacy was statistically comparable to diclofenac (P = 0.183). Conclusion: The capsaicin-loaded hydrogel patch showed excellent physicochemical characteristics, structural stability, and biocompatibility. Its anti-inflammatory efficacy was on a par with standard diclofenac, supporting its potential as a safe and effective treatment for localized pain and inflammation management with MPS.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.